Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Taisho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Taisho Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Taisho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Taisho Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Taisho Pharmaceutical Co., Ltd.'s pipeline products Reasons to buy - Evaluate Taisho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Taisho Pharmaceutical Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Taisho Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Taisho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taisho Pharmaceutical Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Taisho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Taisho Pharmaceutical Co., Ltd. Snapshot 5 Taisho Pharmaceutical Co., Ltd. Overview 5 Key Information 5 Key Facts 5 Taisho Pharmaceutical Co., Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 Taisho Pharmaceutical Co., Ltd. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Taisho Pharmaceutical Co., Ltd. - Pipeline Products Glance 13 Taisho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Taisho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Taisho Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 Taisho Pharmaceutical Co., Ltd. - Drug Profiles 18 TS-091 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 luseogliflozin 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 TS-111 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 TS-121 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 MGS-0028 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Inhibit 50S RNA for Bacterial Infections 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 TASP-0415914 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 TKM-0150 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 TASP-0376377 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Taisho Pharmaceutical Co., Ltd. - Pipeline Analysis 29 Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Target 29 Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 31 Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 32 Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 33 Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates 34 Taisho Pharmaceutical Co., Ltd. - Dormant Projects 35 Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 36 Discontinued Pipeline Product Profiles 36 EPI-2010 36 TS-033 36 parogrelil 36 TS-022 36 Taisho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Taisho Pharmaceutical Co., Ltd., Key Information 5 Taisho Pharmaceutical Co., Ltd., Key Facts 5 Taisho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 8 Taisho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 9 Taisho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 10 Taisho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 11 Taisho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12 Taisho Pharmaceutical Co., Ltd. - Phase II, 2014 13 Taisho Pharmaceutical Co., Ltd. - Phase I, 2014 14 Taisho Pharmaceutical Co., Ltd. - Preclinical, 2014 15 Taisho Pharmaceutical Co., Ltd. - Discovery, 2014 16 Taisho Pharmaceutical Co., Ltd. - Unknown, 2014 17 Taisho Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 30 Taisho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 31 Taisho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 32 Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 33 Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 34 Taisho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 35 Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 36 Taisho Pharmaceutical Co., Ltd., Other Locations 37 Taisho Pharmaceutical Co., Ltd., Subsidiaries 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.